R&D is the lifeline of Pharma business. The Sun Pharma fosters excellence through innovation, supported by strong Research & Development (R&D) capabilities across units, with 6.1% of annual revenue being invested in R&D.
A leading Indian multinational pharma company Sun Pharmaceutical Industries Limited (Sun Pharma) has made significant advances in the pharmaceutical science and it has invested Rs. 20 Billion (Rs.2000 Crore) at 6.1% of total sales in Research and Development (R&D) in FY 2019-20 to enhance R&D capacities, innovation, inventing and developing new medicines with the team of more than 2000 scientists worldwide.
R&D investments for the year 21819 were Rs. 20 Billion (6.9% of total sales). Cumulative R&D spending reached the highest level of Rs. 170 Billion during the Year 2019-20.
“We continue to be disciplined in identifying future R&D projects for the US generics market and the focus is on developing differentiated generics. Investments for developing the long-term specialty pipeline are expected to continue.”, the company’s annual report 2020 said.
R&D is also absolutely vital for strengthening our global specialty pipeline. It is a key determinant of the future growth and profitability of the specialty initiative. We expect to continue to invest in specialty R&D in the coming years as we progress further in building the specialty business, the company said.
“We will continue to focus on growing each of our businesses faster than the market in which we operate. R&D investments in developing a differentiated generic pipeline as well as in building our specialty pipeline will continue in the coming years.”, Dilip Shanghvi, Managing Director, Sun Pharmaceutical Industries Ltd said
R&D is imperative for any pharmaceutical company’s future. Our focus is to continue investing in R&D to develop differentiated generics and innovative specialty products. Our global generic business requires a constant flow of new products and hence R&D capabilities to develop such products and meet the individual requirements of each market are very important. At Sun Pharma, we have multiple R&D centres and a strong R&D
team to cater to these requirements, the report said.
The Company’s R&D capabilities are supported by best-in-class technologies, helping it deliver affordable products globally. Sun Pharma has 43 world-class manufacturing facilities across six continents, enabling the Company to manufacture high‑quality and low-cost products to serve patients globally.
The Sun Pharma fosters excellence through innovation, supported by strong Research & Development (R&D) capabilities across units, with 6.1% of annual revenue being invested in R&D.
